This month, Novartis submitted a letter to the FDA in support of a citizen petition that Pfizer filed in August.
This month, Novartis submitted a letter to the FDA in support of a citizen petition that Pfizer filed in August.
Pfizer’s citizen petition called on the agency to issue guidance clarifying how drug sponsors may communicate about biosimilars, alleging that misinformation communicated to patients, payers, and prescribers, is hindering the growth of the US biosimilar market.
In its comment letter, Novartis explained that it supports the recent efforts from the FDA and HHS to increase the use of biosimilars, specifically, releasing the Biosimilar Action Plan, holding a public hearing in September 2018, and initiating dialogue around key biosimilar topics through the American Patients First blueprint. However, Novartis notes that it believes the FDA and HHS “could do more to incentivize the use of biosimilars while still ensuring access to and development of novel biological products.”
The letter goes on to discuss the importance of accurate information about biosimilars being disseminated to the public, sharing in Pfizer’s concern, and specifically calling on the FDA and HHS to address multiple “misinformation campaigns” that it believes are hurting biosimilar uptake.
Novartis states that the following misinformation campaigns do not provide balanced information about biosimilar products “but rather infer potential risks and aim at casting doubts about their safety or efficacy”:
The letter also cited results seen in a recent report from FirstWord Pharma that found that 33% of respondents said they had heard negative feedback about biosimilars. “There appears to be a particular strategy among some originator companies to openly question the quality of biosimilars, in addition to negative discussion about their efficacy and safety,” concluded the report.
In order to address these issues, Novartis agreed with Pfizer on the need for additional FDA action and oversight “to help ensure a truthful environment exists within which healthcare providers and patients can make treatment decisions without harmful misinformation about biosimilars.”
Specifically, Novartis recommends that the FDA take the following actions: partner with the Federal Trade Commissioner to identify and address these campaigns, issue correspondence directing these organizations to stop publishing misinformation campaigns, establish a public list of which companies or organizations are conducting such campaigns, and enhance educational outreach efforts to contest the campaigns.
Finally, Novartis encouraged the FDA to publish a “Facts About Biosimilars” page on its website to address the most common misinformation and misunderstood elements about biosimilars. In order to deliver the content to a broader audience, Novartis suggested that the FDA work with and leverage relationships with healthcare provider organizations as well as patient advocacy organizations to ensure their members have access to it.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.